Trials / Completed
CompletedNCT05465681
Study of HR20013 for Injection in Patients With Malignant Solid Tumors
A Phase I Clinical Study of Safety and Pharmacokinetics of Single-dose HR20013 for Injection Combined With Dexamethasone in Patients With Malignant Solid Tumors Receiving Cisplatin-based Chemotherapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and pharmacokinetics of single-dose HR20013 for injection combined with dexamethasone in patients with malignant solid tumors receiving cisplatin-based chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR20013 for injection；dexamethason | HR20013 for injection；Drug for preventing nausea and vomiting caused by chemotherapy. dexamethasone: Drug for preventing nausea and vomiting caused by chemotherapy |
Timeline
- Start date
- 2022-08-30
- Primary completion
- 2023-01-13
- Completion
- 2023-01-13
- First posted
- 2022-07-20
- Last updated
- 2023-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05465681. Inclusion in this directory is not an endorsement.